Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,249,575 shares of the medical research company's stock after purchasing an additional 196,864 shares during the period. Vanguard Group Inc. owned about 8.69% of Thermo Fisher Scientific worth $17,297,426,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. FMR LLC lifted its position in shares of Thermo Fisher Scientific by 19.7% during the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after purchasing an additional 1,294,453 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Thermo Fisher Scientific by 68,617.0% during the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after buying an additional 761,649 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $377,901,000. Lindsell Train Ltd acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $211,858,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 15.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,810,128 shares of the medical research company's stock worth $1,461,913,000 after purchasing an additional 366,191 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 over the last quarter. Company insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Trading Down 0.4 %
Shares of Thermo Fisher Scientific stock traded down $1.98 during trading hours on Thursday, reaching $511.69. The stock had a trading volume of 1,249,700 shares, compared to its average volume of 1,534,660. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The firm has a market capitalization of $193.04 billion, a price-to-earnings ratio of 30.96, a P/E/G ratio of 2.99 and a beta of 0.79. The firm has a 50 day simple moving average of $542.80 and a two-hundred day simple moving average of $553.64.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.
Wall Street Analyst Weigh In
TMO has been the topic of a number of recent analyst reports. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a report on Friday, January 31st. Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. UBS Group lifted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $653.23.
Check Out Our Latest Analysis on TMO
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
